Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,865 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Autism, Asperger's Syndrome, Generalized Anxiety Disorder, Social Phobia, Separation Anxiety Disorder, Obsessive-compulsive Disorder
Interventions: Computer assisted cognitive behavioral therapy.; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 7 Years to 12 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Tobacco Dependence
Interventions: C-Raven Virtual Tobacco Cessation Counseling, Nicotine Replacement Product, Community Health Worker, Lung Cancer Screening; Behavioral · Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Instrument Assisted Soft Tissue Mobilization, Walking Treatment; Other
Lead sponsor: Beth Marschner; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Minot, North Dakota

Conditions: Cerebral Palsy, Hemiplegic Cerebral Palsy, Spastic Hemiplegic Cerebral Palsy, Spastic Hemiparesis, Spastic Hemiplegia
Interventions: active transcranial direct current stimulation, bimanual training; Device · Behavioral
Lead sponsor: Burke Medical Research Institute; Other
Eligibility: 6 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more

Conditions: Low Back Pain, Patient Acceptance of Health Care, Veterans Health
Interventions: Chiropractic Care; Other
Lead sponsor: Palmer College of Chiropractic; Other
Eligibility: 18 Years and older
Enrollment: 766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Los Angeles, California • West Haven, Connecticut • Iowa City, Iowa + 1 more

Conditions: Posterior Blepharoconjunctivitis
Interventions: Azithromycin ophthalmic solution, 1%; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteer
Interventions: Alectinib, Esomeprazole, High Fat and Calorie Meal, Standard Meal; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Blood Coagulation Disorders, Hemophilia A
Interventions: Recombinant Factor VIII (BAY81-8973), Recombinant Factor VIII (Kogenate FS, BAY14-2222); Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Orange, California • Sacramento, California • Tampa, Florida + 4 more

Conditions: Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
Interventions: LY2127399, Placebo every 2 weeks, Placebo every 4 weeks, Standard of Care; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 88
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 85 more

Conditions: B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, T-Cell Prolymphocytic Leukemia
Interventions: Letermovir; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Retinal Disease, Macular Disease
Interventions: Interferon gamma-1b; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Low Grade Glioma
Interventions: Carboplatin and Vincristine, Carboplatin; Drug
Lead sponsor: Alicia Lenzen; Other
Eligibility: Up to 21 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 21
States / cities: Phoeniz, Arizona • San Diego, California • New Haven, Connecticut + 17 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: ION363, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 8
States / cities: La Jolla, California • Palo Alto, California • Baltimore, Maryland + 5 more

Conditions: Chronic Low-back Pain
Interventions: Intervention to Reduce Sedentary Time; Behavioral
Lead sponsor: Iowa State University; Other
Eligibility: 25 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Temporomandibular Disorders (TMD)
Interventions: Standard care, Physical Therapy (PT); Other
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Anterior Cruciate Ligament Injuries, Post-traumatic Osteoarthritis, Knee Osteoarthritis, Osteo Arthritis Knee, Knee Injuries, Cartilage, Articular, Gait
Interventions: Real-time gait biofeedback, Sham real-time gait biofeedback; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 35 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Care Transition
Interventions: Structured hand-off, Medication reconciliation during transitional period, Transitional medication monitoring, Teleconsultation; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Osteoarthritis
Interventions: OA-PCP Intervention, Attention Control; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 65 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Keratoconus, Ectasia
Interventions: Ricrolin+, VEGA UV-A system; Drug · Device
Lead sponsor: Center for Sight, Sacramento, CA; Other
Eligibility: 12 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Anemia, Iron-deficiency
Interventions: Ferric Maltol, Ferrous sulfate; Drug
Lead sponsor: Shield Therapeutics; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 14
States / cities: Saraland, Alabama • Homestead, Florida • Kissimmee, Florida + 10 more

Conditions: Stress Reduction
Interventions: FertiStrong App; Behavioral
Lead sponsor: Fertility Centers of Illinois; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Suicide Risk
Interventions: TIPS Program, TIPS Program + ED-SAFE; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 32,406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Pregnancy Related
Interventions: Pregnant women exposed to tildrakizumab, Pregnant women not exposed to tildrakizumab; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Computer- Assisted Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders

C-Raven, a Virtual Tobacco Cessation Intervention in the Community

Effects of Instrument Assisted Soft Tissue Mobilization on Healthy Tissue Regarding Range of Motion and Gait

tDCS and Bimanual Therapy for Children With Hemiplegic Cerebral Palsy

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Veterans Response to Dosage in Chiropractic Therapy

A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)

A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Topical Interferon Gamma-1b for Central Serous Chorioretinopathy

A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

Reducing Sedentary Time in Chronic Low Back Pain: Sedentary Intervention Using Motivational Interviewing and Technology

The Effect of Manual Physical Therapy and Exercise in Addition to Routine Dental Care in Individuals With Temporomandibular Disorders

Gait Rehabilitation to Treat FastOA

Preventing Medication-Related Problems in Care Transitions to Skilled Nursing Facilities

Physical Activity Pathway for Patients With Osteoarthritis in Primary Care (OA-PCP) (R33)

Corneal Collagen Cross-Linking (CXL) Performed With "Epi-ON" Versus "Epi-OFF" in Eyes With Keratoconus and Other Corneal Ectatic Disorders

Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years

The Impact of a Self-help Coping App on Distress Levels in Men Experiencing Infertility

Telehealth to Improve Prevention of Suicide (TIPS)

Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab